A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

NCT04903509 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

95

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BI 1820237
DRUG: Placebo
DRUG: Saxenda®
DRUG: Paracetamol-ratiopharm®

Sponsor

Boehringer Ingelheim